Ascentage Pharma (AAPG) Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug candidate in the Company’s pipeline, in combination with azacitidine in patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies in a poster presentation at the 67th American Society of Hematology, ASH, Annual Meeting, being held in Orlando, Florida. Data featured in the report further validated the therapeutic potential and favorable tolerability profile of Lisaftoclax in myeloid malignancies, including treatment responses from venetoclax-resistant patients. These results underscore Lisaftoclax’s distinct clinical value that is differentiated from other drugs in the same class.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
- Ascentage Pharma initiated with an Outperform at Oppenheimer
- Ascentage Pharma management to meet with Oppenheimer
- Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast
- Ascentage Pharma Announces New RSU and Share Option Grants